133 related articles for article (PubMed ID: 36006675)
1. CAR-T for follicular lymphoma: are we good to go?
Gasiorowski R; Trotman J
Blood; 2022 Aug; 140(8):799-800. PubMed ID: 36006675
[No Abstract] [Full Text] [Related]
2. The evolving use of CAR T-cell therapy in follicular lymphoma.
Nastoupil LJ
Clin Adv Hematol Oncol; 2021 Nov; 19(11):684-686. PubMed ID: 34807012
[No Abstract] [Full Text] [Related]
3. CAR T cell therapy for B-cell lymphomas.
Chavez JC; Locke FL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
[TBL] [Abstract][Full Text] [Related]
4. Timing of CAR-T therapy in follicular lymphoma.
Alhaj Moustafa M
Expert Rev Anticancer Ther; 2023 Apr; 23(4):347-349. PubMed ID: 36825538
[No Abstract] [Full Text] [Related]
5. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
[TBL] [Abstract][Full Text] [Related]
6. What are the key considerations for deciding on the use of CAR T-cell therapy for patients with follicular lymphoma?
Hunter B
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1159-1161. PubMed ID: 36205516
[No Abstract] [Full Text] [Related]
7. Rapid response in relapsed follicular lymphoma with massive chylous ascites to anti-CD19 CAR T therapy using Piggy Bac: A case report.
Zhang Y; Lin Z; Zhang F; Chen X; Yang Y; Fu X; Li Z; Sun Y; Qian Q
Front Immunol; 2022; 13():1007210. PubMed ID: 36532014
[TBL] [Abstract][Full Text] [Related]
8. Significant response of patients with transformed follicular lymphoma with rapid disease progression to CAR-T therapy.
Hirano T; Tatetsu H; Ueno S; Shichijo T; Furukawa S; Tsujihashi M; Miyakawa T; Shiraishi S; Higuchi Y; Uchiba M; Yasunaga JI; Nosaka K; Matsuoka M
J Clin Exp Hematop; 2023 Dec; 63(4):266-269. PubMed ID: 38030235
[No Abstract] [Full Text] [Related]
9. Successful treatment of a case with synchronous follicular lymphoma and gastric adenocarcinoma with CD19 CAR T cells and literature review.
Liu J; Cao F; Li Z; Gao H; Zhang C; Du T; Li Z; Song Y; Zhu J; Ying Z
J Clin Pharm Ther; 2022 Sep; 47(9):1466-1470. PubMed ID: 35437775
[TBL] [Abstract][Full Text] [Related]
10. CAR-T cells, from principle to clinical applications.
Bourbon E; Ghesquières H; Bachy E
Bull Cancer; 2021 Oct; 108(10S):S4-S17. PubMed ID: 34920806
[TBL] [Abstract][Full Text] [Related]
11. [CAR-T cells in lymphomas: Current and evolving role].
Messéant O; Houot R
Bull Cancer; 2021 Oct; 108(10S):S28-S39. PubMed ID: 34920805
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
[TBL] [Abstract][Full Text] [Related]
13. Beyond CD19 CAR-T cells in lymphoma.
Leung WK; Ayanambakkam A; Heslop HE; Hill LC
Curr Opin Immunol; 2022 Feb; 74():46-52. PubMed ID: 34800921
[TBL] [Abstract][Full Text] [Related]
14. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
[TBL] [Abstract][Full Text] [Related]
15. What a headache! Double-hit lymphoma with CNS recurrence - Role of chimeric antigen receptor (CAR) T-cell therapy.
Rafelson W; Olszewski A
Leuk Lymphoma; 2020 Apr; 61(4):757-762. PubMed ID: 31762352
[No Abstract] [Full Text] [Related]
16. Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.
Ravi D; Sarkar S; Purvey S; Passero F; Beheshti A; Chen Y; Mokhtar M; David K; Konry T; Evens AM
Leukemia; 2020 May; 34(5):1291-1304. PubMed ID: 31772298
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Wang Y; Cao J; Gu W; Shi M; Lan J; Yan Z; Jin L; Xia J; Ma S; Liu Y; Li H; Pan B; Chen W; Fei X; Wang C; Xie X; Yu L; Wang G; Li H; Jing G; Cheng H; Zhu F; Sun H; Sang W; Li D; Li Z; Zheng J; Xu K
J Clin Oncol; 2022 Jul; 40(20):2246-2256. PubMed ID: 35333600
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
Levin A; Shah NN
Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
[TBL] [Abstract][Full Text] [Related]
19. Preliminary outcomes reported from three randomized controlled trials of CD19 CAR-T cell therapies in large B cell lymphoma.
Jain MD
Mol Ther; 2022 Jan; 30(1):14-16. PubMed ID: 34921770
[No Abstract] [Full Text] [Related]
20. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
